SIRT1 and chronic myelogenous leukemia, BCR-ABL1 positive: In CML, the involvement of SIRT1 in the maintenance of leukemogenesis and in the acquisition of chemoresistance poses a window of opportunity as a therapeutic target that is already beginning to be explored (Figure 2).